Matcha, a powdered green tea, ameliorates the progression of renal and hepatic damage in type 2 diabetic OLETF rats

Journal of Medicinal Food

Volumn 12, Issue 4, 2009, Pages 714-721

  Yamabe, Noriko ^a   Kang, Ki Sung ^a   Hur, Jong Moon ^a   Yokozawa, Takako ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Advanced glycation end products; Matcha; Sterol regulatory element binding proteins; Type 2 diabetes

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CHOLESTEROL; GLUCOSE; GLYCOSYLATED PROTEIN; LIVER PROTECTIVE AGENT; LYSINE DERIVATIVE; MATCHA; N EPSILON CARBOXYETHYLLYSINE; PROTEIN; SERUM ALBUMIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URINARY TRACT AGENT;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; KIDNEY INJURY; LIVER INJURY; LIVER PROTECTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; TEA; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PROTEINS; CAMELLIA SINENSIS; CHOLESTEROL; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; KIDNEY; LIVER; LYSINE; PHYTOTHERAPY; PLANT EXTRACTS; POWDERS; RATS; RATS, INBRED OLETF; RECEPTORS, IMMUNOLOGIC; SERUM ALBUMIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TEA; THIOBARBITURATES; TRIGLYCERIDES;

RATTUS;

EID: 70149122365     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2008.1282     Document Type: Article

References (36)

1. Bray GA: Pathophysiology of obesity. Am J Clin Nutr 1992;55 (2 Suppl):S488-494S.
2. Barness LA, Opitz JM, Gilbert-Barness E: Obesity: genetic, molecular, and environmental aspects. Am J Med Genet A 2007;143:3016-3034.
3. Pontiroli AE, Galli L: Duration of obesity is a risk factor for non-insulin-dependent diabetes mellitus, not for arterial hypertension or for hyperlipidaemia. Acta Diabetol 1998;35:130-136.
4. Felber JP, Golay A: Pathways from obesity to diabetes. Int J Obes Relat Metab Disord 2002;26(Suppl 2):S39-S45.
5. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
6. Rolo AP, Palmeira CM: Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Phar-macol 2006;212:167-178.
7. Shah S, Iqbal M, Karam J, Salifu M, McFarlane SI: Oxidative stress, glucose metabolism, and the prevention of type 2 diabetes: pathophysiological insights. Antioxid Redox Signal 2007;9:911-929.
8. Ahmed N: Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract 2005;67: 3-21.
9. Taskinen MR: Type 2 diabetes as a lipid disorder. Curr Mol Med 2005;5:297-308.
10. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T: Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992;41:1422-1428.
11. Seo YS, Kim JH, Jo NY, Choi KM, Baik SH, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH, Kim A, Yeon JE: PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastro-enterol Hepatol 2008;23:102-109.
12. Rahbar S, Figarola JL: Inhibitors and breakers of advanced glycation endproducts (AGEs): a review. Curr Med Chem Im-munol Endocrinol Metab Agents 2002;2:135-161.
13. Mensink M: Lifestyle intervention, glucose tolerance, and risk of developing type 2 diabetes mellitus. Metab Syndr Relat Disord 2005;3:26-34.
14. Rahimi R, Nikfar S, Larijani B, Abdollahi M: A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother 2005;59:365-373.
15. Yamabe N, Yokozawa T, Oya T, Kim M: Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats. J Pharmacol Exp Ther 2006;319:228-236.
16. McFarland KF, Catalano EW, Day JF, Thorpe SR, Baynes JW: Nonenzymatic glucosylation of serum proteins in diabetes mel-litus. Diabetes 1979;28:1011-1014.
17. Naito C, Yamanaka T: Lipids peroxides in atherosclerotic diseases. Nippon Ronen Igakkai Zasshi 1978;15:187-191.
18. Momose T, Yano Y, Ohashi K: Organic analysis. XLIV. A new deproteinizing agent for determination of blood sugar. Chem Pharm Bull 1963;11:968-972.
19. Nakayama H, Mitsuhashi T, Kuwajima S, Aoki S, Kuroda Y, Itoh T, Nakagawa S: Immunochemical detection of advanced glycation end products in lens crystallins from streptozocin-induced diabetic rat. Diabetes 1993;42:345-350. (Pubitemid 23045041)
20. Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497-509.
21. Rangan GK, Wang Y, Tay YC, Harris DCH: Inhibition of nuclear factor-kB activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int 1999;56:118-134.
22. Standard tables of food composition in Japan. Fifth revised and enlarged edition. In: Report of the Subdivision on Resources. The Council for Science and Technology, Ministry of Education, Culture, Sports, Science and Technology, Tokyo, 2005, pp. 228-229.
23. McKay DL, Blumberg JB: The role of tea in human health: an update. J Am Coll Nutr 2002;21:1-13.
24. Cabrera C, Artacho R, Gime ́nez R: Beneficial effects of green tea-a review. J Am Coll Nutr 2006;25:79-99.
25. Scheen AJ: Current management strategies for coexisting diabetes mellitus and obesity. Drugs 2003;63:1165-1184.
26. Wright E Jr, Scism-Bacon JL, Glass LC: Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract 2006;60:308-314.
27. Hyogo H, Yamagishi S: Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des 2008;14:969-972. (Pubitemid 351753284)
28. Heidland A, Sebekova K, Schinzel R: Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 2001;38(4 Suppl 1):S100-S106. (Pubitemid 32927622)
29. Horton JD, Goldstein JL, Brown MS: SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-1131.
30. Ide T, Shimano H, Yahagi N, Matsuzaka T, Nakakuki M, Yamamoto T, Nakagawa Y, Takahashi A, Suzuki H, Sone H, Toyoshima H, Fukamizu A, Yamada N: SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat Cell Biol 2004;6: 351-357.
31. Bugianesi E, McCullough AJ, Marchesini G: Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005;42: 987-1000.
32. Morino K, Petersen KF, Shulman GI: Molecular mechanisms of insulin resistance in humans and their potential links with mi-tochondrial dysfunction. Diabetes 2006;55(Suppl 2):S9-S15.
33. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Alema ́n JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Ste-phanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR: Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 2008;7:125-134.
34. Leff T: AMP-activated protein kinase as a therapeutic target for diabetes. Drug Discov Today Ther Strateg 2007;4:123-127.
35. Koyama Y, Abe K, Sano Y, Ishizaki Y, Njelekela M, Shoji Y, Hara Y, Isemura M: Effects of green tea on gene expression of hepatic gluconeogenic enzymes in vivo. Planta Med 2004;70: 1100-1102.
36. Collins QF, Liu HY, Pi J, Liu Z, Quon MJ, Cao W: Epigallo-catechin-3- gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5'-AMP-activated protein ki-nase. J Biol Chem 2007;282:30143-30149.